



STARPHARMA GRANTED ADDITIONAL NANOTECHNOLOGY PATENT IN USA

Melbourne (Australia), 7 June 2004: Starpharma Holdings Limited (ASX:SPL) has received notification of issue of US Patent Number 6740635 "Antiviral linear polymers" from the United States Patent and Trademark Office. The patent is exclusively licensed by the Biomolecular Research Institute Limited to Starpharma Limited, a wholly-owned subsidiary of Starpharma Holdings Limited.

The patent expands Starpharma's coverage to non-dendrimer based scaffoldings in specific areas of anti-viral activity. Dendrimers remain the most precise nanotech structures and will continue to be the main focus of Starpharma's drug development activities.

In response to the issuance of the patent, Starpharma CEO Dr. John Raff stated "It is always a significant milestone to have a patent issued in the United States and we are continuing to expand our patent coverage in nanotechnology based pharmaceuticals."

Starpharma Holdings Limited (ASX:SPL) is focused on the development and application of dendrimer nanotechnologies as drugs against major diseases. Starpharma's lead dendrimer product, VivaGel™ has received clearance from the US FDA for human clinical trials. VivaGel™ is a topical microbicide gel product that has been developed for women as a preventative against the sexual transmission of HIV. It is also active in animal studies for the prevention of other sexually transmitted diseases including Genital Herpes and Chlamydia. SPL also has an equity interest in a US based company – Dendritic Nanotechnologies, Inc. (DNT) – established with the US pioneer of dendrimer nanotechnology Dr Donald Tomalia.

CONTACTS:

Dr John Raff
Chief Executive Officer
+61 3 8532 2701

Mr Ben Rogers
Company Secretary
+61 3 8532 2702

www.starpharma.com